KD 5170

Discontinued Product

KD 5170 (Cat. No. 4001) has been withdrawn from sale for commercial reasons.
Cat.No. 4001 - KD 5170 | C20H25N3O5S2 | CAS No. 940943-37-3
Description: Class I and II histone deacetylase (HDAC) inhibitor
Chemical Name: S-[2-[6-[[[4-[3-(Dimethylamino)propoxy]phenyl]sulfonyl]amino]-3-pyridinyl]-2-oxoethyl]ethanethioc acid ester
Purity: ≥95% (HPLC)
Datasheet
Citations
Reviews
Literature

Biological Activity

Class I and II histone deacetylase (HDAC) inhibitor (IC50 = 0.045 μM; EC50 = 0.025 μM in HeLa screening and HeLa cell-based assays, respectively). Exhibits broad spectrum inhibition of HDAC classes I and II in assays using purified recombinant human isoforms. Displays less potent inhibition of HDAC2 (IC50 values are 0.014, 0.020, 0.026, 0.075 and 2.0 μM for HDAC6, HDAC1, HDAC4, HDAC3 and HDAC2 respectively). Displays cytotoxicity against numerous cell lines derived from human tumors. Orally available.

Compound Libraries

KD 5170 is also offered as part of the Tocriscreen Epigenetics Toolbox. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 451.56
Formula C20H25N3O5S2
Storage Store at -20°C
Purity ≥95% (HPLC)
CAS Number 940943-37-3
Smiles O=C(CSC(C)=O)C(C=N2)=CC=C2NS(C1=CC=C(OCCCN(C)C)C=C1)(=O)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

References

References are publications that support the biological activity of the product.

Feng et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Mol.Cancer Ther. 7 1494 PMID: 18566220

Hassig et al (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad-spectrum antitumor activity in vitro and in vivo. Mol.Cancer Ther. 7 1054 PMID: 18483295

Payne et al (2008) Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor. Bioorg.Med.Chem.Lett. 18 6093 PMID: 18954983

View Related Products by Product Action

View all Non-selective Histone Deacetylase Inhibitors

Keywords: KD 5170, KD 5170 supplier, antitumor, antitumour, hdacs, histone, deacetylases, inhibitors, inhibits, KD5170, epigenetics, Non-selective, HDACs, Non-Selective, 4001, Tocris Bioscience

Citations for KD 5170

Citations are publications that use Tocris products.

Currently there are no citations for KD 5170.

Reviews for KD 5170

There are currently no reviews for this product. Be the first to review KD 5170 and earn rewards!

Have you used KD 5170?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Epigenetics

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics

Epigenetics Research Bulletin

Produced by Tocris and updated in 2014, the epigenetics research bulletin gives an introduction into mechanisms of epigenetic regulation, and highlights key Tocris products for epigenetics targets including:

  • Bromodomains
  • DNA Methyltransferases
  • Histone Deacetylases
  • Histone Demethylases
  • Histone Methyltransferases
Rheumatoid Arthritis

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.